Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Search strategy defined by population, concept, context framework, with Boolean operators. by Emily M. Jones (21989800)

Subjects:

Rspo3 decreases c-fos IF intensity in rRPa. by Kenji Uno (548200)

Patient enrollment and inclusion information. by Ruitian Song (11045127)

Subjects:

Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

Details of included studies that measured patient impact. by Emily M. Jones (21989800)

Subjects:

Proportion of child participants who defined trust, by age and component described. by Alex R. Wheeler (21453462)

Proportion of adult participants who defined trust, by condition and component described. by Alex R. Wheeler (21453462)

Experimental validation revealed that ACADSB and ACADM decreased in patients with UC. by Hongliang Chen (538815)

Studies measuring patient-level impact (N = 6, 19% of included studies). by Emily M. Jones (21989800)

Subjects:

Studies measuring provider-level impact (N = 26, 81% of included studies). by Emily M. Jones (21989800)

Subjects:

Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart. by Emily M. Jones (21989800)

Subjects:

Study demographics of all included studies. by Emily M. Jones (21989800)

Subjects:

(a) Market share and (b) shareweight for reference and three defined high battery-based electric vehicle scenarios. by Pankaj Sadavarte (2012029)

Naringenin decreases mitochondrial function. by Lauren A. Eanes (20995499)

Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

“…In contrast, s-ketamine largely preserved respiratory variability, suggesting it may be a safer alternative for sedation in patients with impaired spontaneous breathing. Further studies are needed to assess the clinical implications of these observations in patients undergoing sedation.…”

Naringenin decreases total cell viability. by Lauren A. Eanes (20995499)

Table_2_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.xlsx by Kristin R. Anderson (5478734)

Image_1_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.jpg by Kristin R. Anderson (5478734)

Table_1_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.pdf by Kristin R. Anderson (5478734)